AACR Congratulates William S. Dalton on 2010 Leadership in Personalized Medicine Award
PHILADELPHIA — The American Association for Cancer Research expresses its congratulations to and appreciation of William S. Dalton, M.D., Ph.D., who will receive the 2010 Leadership in Personalized Medicine Award from the Personalized Medicine Coalition (PMC).
Dalton, who has been a distinguished member of the AACR for more than 20 years, will receive the award from the PMC at the Harvard Personalized Medicine Conference on Nov. 17. According to the PMC, he is recognized for “his pioneering work putting the concepts of personalized medicine into practice for the benefit of patients.”
Dalton is the chief executive officer of the H. Lee Moffitt Cancer Center in Tampa, Fla. He also serves as chair of the AACR’s Science Policy and Legislative Affairs Committee.
“This is a wonderful and fitting honor for Dr. Dalton, who is at the forefront of personalized medicine and whose work has benefitted countless cancer patients,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “Moreover, Dr. Dalton’s contributions extend beyond the lab and clinic to the halls of Congress. As chair of the AACR’s Science Policy and Legislative Affairs Committee, he convenes the committee that guides the AACR’s policy efforts. Dr. Dalton is a leader who is impacting the field on many levels, and we celebrate his achievement.”
Dalton received his doctoral degree in toxicology and medical life sciences and his medical degree from Indiana University. He completed his internship in internal medicine at Indiana University, his residency in medicine at the University of Arizona in Tucson and his fellowships in oncology and clinical pharmacology at the University of Arizona. He is board certified in internal medicine and medical oncology and is an expert in multiple myeloma.
The PMC Award recognizes an individual whose contributions in science, business and/or policy have helped advance the frontiers of personalized medicine.
# # #
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.